Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:pentose
go back to main search page
Accession:CHEBI:25901 term browser browse the term
Definition:A five-carbon monosaccharide which in its linear form contains either an aldehyde group at position 1 (aldopentose) or a ketone group at position 2 (ketopentose).
Synonyms:related_synonym: pentoses



show annotations for term's descendants           Sort by:
 
2'-deoxycytosine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance
ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Deoxycytidine Monophosphate] CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
2'-deoxyguanosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 multiple interactions ISO [9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein; Deoxycytidine inhibits the reaction [[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein] CTD PMID:9297556 PMID:9403342 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO CYP1A1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine] CTD PMID:21907773 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO CYP1A2 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP1A2 protein promotes the reaction [Estrone binds to Deoxyguanosine] CTD PMID:21907773 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO CYP1B1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine] CTD PMID:21907773 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO CYP3A4 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP3A4 protein promotes the reaction [Estrone binds to Deoxyguanosine] CTD PMID:21907773 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase decreases activity ISO Deoxyguanosine analog results in decreased activity of MGMT protein CTD PMID:17880193 NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
JBrowse link
2'-deoxyguanosine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance
ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 2'-deoxyguanosine 5'-phosphate] CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
2-deoxy-alpha-D-ribose 1-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Tymp thymidine phosphorylase increases abundance ISO TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate CTD PMID:11103787 NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874
JBrowse link
2-deoxy-D-ribofuranose 1-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Tymp thymidine phosphorylase increases abundance ISO TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate CTD PMID:11103787 NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874
JBrowse link
3',5'-cyclic AMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 increases expression
multiple interactions
ISO Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein
[HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein
CTD PMID:20339114 PMID:20655299 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 increases transport
multiple interactions
affects uptake
ISO ABCC4 protein results in increased transport of Cyclic AMP
Probenecid affects the reaction [ABCC4 protein affects the uptake of Cyclic AMP analog]
CTD PMID:11856762 PMID:28587784 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 multiple interactions ISO [ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:7733904 NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases abundance ISO ADIPOQ protein results in increased abundance of Cyclic AMP CTD PMID:18931039 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Adm adrenomedullin multiple interactions
increases abundance
EXP ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]
ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP
CTD PMID:10374718 PMID:17306419 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
JBrowse link
G Adra1b adrenoceptor alpha 1B multiple interactions ISO ADRA1B protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP] CTD PMID:12649302 NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
JBrowse link
G Adrb1 adrenoceptor beta 1 multiple interactions
increases abundance
affects abundance
ISO
EXP
[3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]
ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP
ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]
CTD PMID:11562432 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 More... NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions
increases chemical synthesis
increases abundance
affects abundance
EXP
ISO
[Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]
ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP
[Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]
ADRB2 protein results in increased abundance of Cyclic AMP
ADRB2 protein affects the abundance of Cyclic AMP
CTD PMID:10516654 PMID:10857765 PMID:10952688 PMID:11562432 PMID:12920204 More... NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
JBrowse link
G Adrb3 adrenoceptor beta 3 multiple interactions
affects abundance
ISO 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP
ADRB3 protein affects the abundance of Cyclic AMP
CTD PMID:10952688 PMID:14730417 NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
JBrowse link
G Ahcyl1 adenosylhomocysteinase-like 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of AHCYL1 mRNA] CTD PMID:19414516 NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815
JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
decreases expression
EXP
ISO
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA
Cyclic AMP results in decreased expression of AHR protein
CTD PMID:12859982 PMID:32781018 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA CTD PMID:16036225 NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
JBrowse link
G Angptl4 angiopoietin-like 4 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANGPTL4 mRNA] CTD PMID:19414516 NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
JBrowse link
G Ank2 ankyrin 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANK2 mRNA] CTD PMID:19414516 NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) multiple interactions
increases expression
ISO N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA] CTD PMID:12542607 NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
JBrowse link
G Aqp5 aquaporin 5 multiple interactions ISO Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein CTD PMID:15536076 NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
JBrowse link
G Armh4 armadillo-like helical domain containing 4 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ARMH4 mRNA] CTD PMID:19414516 NCBI chr15:22,975,895...23,076,986
Ensembl chr15:22,975,895...23,076,949
JBrowse link
G Arnt aryl hydrocarbon receptor nuclear translocator multiple interactions EXP Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein] CTD PMID:12859982 NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
JBrowse link
G Arrb2 arrestin, beta 2 multiple interactions ISO [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein CTD PMID:25191754 NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
JBrowse link
G Atf5 activating transcription factor 5 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ATF5 mRNA] CTD PMID:19414516 NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
JBrowse link
G Avp arginine vasopressin multiple interactions ISO [AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:20683494 NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
JBrowse link
G Avpr2 arginine vasopressin receptor 2 multiple interactions
increases abundance
ISO [AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP
AVPR2 protein results in increased abundance of Cyclic AMP
CTD PMID:20683494 PMID:33638691 NCBI chr  X:151,633,501...151,636,000
Ensembl chr  X:151,633,522...151,635,989
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase increases activity
multiple interactions
ISO
EXP
Cyclic AMP results in increased activity of BRAF protein
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein
CTD PMID:21693435 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
JBrowse link
G C1qtnf5 C1q and TNF related 5 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C1QTNF5 mRNA] CTD PMID:19414516 NCBI chr 8:44,450,934...44,453,075
Ensembl chr 8:44,451,154...44,453,074
JBrowse link
G Calca calcitonin-related polypeptide alpha increases abundance
multiple interactions
ISO
EXP
CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP
CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]
Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]
CTD PMID:15297469 PMID:17295025 PMID:17306419 PMID:18463244 NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
JBrowse link
G Carm1 coactivator-associated arginine methyltransferase 1 multiple interactions
increases phosphorylation
ISO [Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] CTD PMID:20360387 NCBI chr 8:20,097,262...20,141,950
Ensembl chr 8:20,097,254...20,147,689
JBrowse link
G Cckbr cholecystokinin B receptor multiple interactions ISO CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] CTD PMID:11880531 NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] CTD PMID:9863660 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA] CTD PMID:19414516 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
JBrowse link
G Ccnd1 cyclin D1 multiple interactions EXP
ISO
[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein] CTD PMID:21693435 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cd3e CD3e molecule decreases phosphorylation ISO Cyclic AMP results in decreased phosphorylation of CD3E protein CTD PMID:2824607 NCBI chr 8:45,303,848...45,315,297
Ensembl chr 8:45,303,852...45,315,022
JBrowse link
G Cd3g CD3g molecule decreases phosphorylation ISO Cyclic AMP results in decreased phosphorylation of CD3G protein CTD PMID:2824607 NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions EXP
ISO
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; Sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein] CTD PMID:21693435 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases response to substance ISO CEBPB protein results in increased susceptibility to Cyclic AMP CTD PMID:23097472 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions
increases activity
ISO
EXP
Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides]
CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]
Cyclic AMP results in increased activity of CFTR protein
Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form]
CTD PMID:11786964 PMID:12529251 PMID:12556293 PMID:12612912 PMID:15229107 More... NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
JBrowse link
G Cga glycoprotein hormones, alpha polypeptide multiple interactions
affects secretion
increases abundance
EXP
ISO
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA
CGA protein affects the secretion of Cyclic AMP
CGA protein results in increased abundance of Cyclic AMP
[CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]
CTD PMID:8404651 PMID:20378682 PMID:21642635 PMID:23071612 PMID:26895433 More... NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
JBrowse link
G Chsy1 chondroitin sulfate synthase 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CHSY1 mRNA] CTD PMID:19414516 NCBI chr 1:119,689,626...119,750,711
Ensembl chr 1:119,686,350...119,750,601
JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions EXP
ISO
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]
CTD PMID:10422789 PMID:11730719 PMID:17953657 PMID:27429655 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
JBrowse link
G Cnr2 cannabinoid receptor 2 multiple interactions ISO (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CTD PMID:17558435 PMID:27429655 NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
JBrowse link
G Cntn1 contactin 1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA CTD PMID:33713149 NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
JBrowse link
G Cp ceruloplasmin multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CP mRNA] CTD PMID:19414516 NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP [Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] CTD PMID:12859982 PMID:22676303 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
JBrowse link
G Crebbp CREB binding protein multiple interactions ISO CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein] CTD PMID:20360387 NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
JBrowse link
G Crh corticotropin releasing hormone multiple interactions ISO
EXP
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]
CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]
CTD PMID:2153673 PMID:20702571 NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
JBrowse link
G Crhr1 corticotropin releasing hormone receptor 1 multiple interactions ISO [CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] CTD PMID:20702571 NCBI chr10:89,040,203...89,083,481
Ensembl chr10:89,040,203...89,083,481
JBrowse link
G Crp C-reactive protein multiple interactions ISO Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA] CTD PMID:22117073 NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO Cyclic AMP results in increased expression of CSF3 protein CTD PMID:7540958 NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
JBrowse link
G Csk C-terminal Src kinase multiple interactions ISO CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]] CTD PMID:1699227 NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
JBrowse link
G Cstb cystatin B multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CSTB mRNA] CTD PMID:19414516 NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526
JBrowse link
G Ctsa cathepsin A multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CTSA mRNA] CTD PMID:19414516 NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 increases expression
multiple interactions
ISO Cyclic AMP results in increased expression of CYP11A1 mRNA
Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein
myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]
CTD PMID:25576683 PMID:28668616 PMID:29228121 NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions
increases expression
ISO [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein
Cyclic AMP results in increased expression of CYP17A1 mRNA
CTD PMID:23084589 PMID:25576683 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 increases expression
multiple interactions
ISO Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]
CTD PMID:29228121 PMID:31953017 NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA CTD PMID:32781018 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions
ISO
EXP
Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer]
CTD PMID:12859982 PMID:32781018 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 multiple interactions
increases expression
ISO Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter]; Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; Dactinomycin inhibits the reaction [Cyclic AMP results in increased expression of CYP2A5 mRNA] CTD PMID:12754101 PMID:18602936 NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
JBrowse link
G Cyp51 cytochrome P450, family 51 increases expression ISO Cyclic AMP results in increased expression of CYP51 mRNA CTD PMID:25576683 NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases expression
decreases activity
EXP Cyclic AMP results in decreased expression of CYP7B1 mRNA
Cyclic AMP results in decreased activity of CYP7B1 protein
CTD PMID:12029625 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
JBrowse link
G Dap death-associated protein multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DAP mRNA] CTD PMID:19414516 NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752
JBrowse link
G Ddt D-dopachrome tautomerase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DDT mRNA] CTD PMID:19414516 NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
JBrowse link
G Disc1 DISC1 scaffold protein multiple interactions ISO Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] CTD PMID:16293762 NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778
JBrowse link
G Dkk1 dickkopf WNT signaling pathway inhibitor 1 affects response to substance ISO DKK1 protein affects the susceptibility to Cyclic AMP CTD PMID:21546446 NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
JBrowse link
G Dld dihydrolipoamide dehydrogenase increases abundance EXP DLD protein results in increased abundance of Cyclic AMP CTD PMID:25981801 NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795
JBrowse link
G Dlg4 discs large MAGUK scaffold protein 4 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA CTD PMID:33713149 NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
JBrowse link
G Drd1 dopamine receptor D1 multiple interactions ISO
EXP
A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]
[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]
CTD PMID:8558425 PMID:15711596 NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions ISO [Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP]
CTD PMID:11880531 PMID:17958328 NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
JBrowse link
G Drd4 dopamine receptor D4 multiple interactions ISO [3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP] CTD PMID:15542745 NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
JBrowse link
G E2f2 E2F transcription factor 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA CTD PMID:33713149 NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] CTD PMID:17295779 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Egr1 early growth response 1 multiple interactions ISO [[Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA CTD PMID:12767924 NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
JBrowse link
G Ehd2 EH-domain containing 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of EHD2 mRNA] CTD PMID:19414516 NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783
JBrowse link
G Endod1 endonuclease domain containing 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENDOD1 mRNA] CTD PMID:19414516 NCBI chr 8:11,209,123...11,238,680 JBrowse link
G Eno2 enolase 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENO2 mRNA] CTD PMID:19414516 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
JBrowse link
G Epo erythropoietin increases expression EXP Cyclic AMP results in increased expression of EPO protein CTD PMID:18621143 NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
JBrowse link
G Errfi1 ERBB receptor feedback inhibitor 1 increases expression EXP Cyclic AMP results in increased expression of ERRFI1 mRNA CTD PMID:1472065 NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions
increases activity
ISO [Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein] CTD PMID:19766106 PMID:20360387 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]
CTD PMID:19766106 PMID:20378682 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G F2r coagulation factor II (thrombin) receptor multiple interactions ISO [C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:22207716 NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
JBrowse link
G F2rl1 F2R like trypsin receptor 1 multiple interactions ISO Cyclic AMP promotes the reaction [F2RL1 protein results in increased transport of Chlorides] CTD PMID:11804840 NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
JBrowse link
G F2rl3 F2R like thrombin or trypsin receptor 3 multiple interactions ISO [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:22207716 NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472
JBrowse link
G Fam20c FAM20C, golgi associated secretory pathway kinase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FAM20C mRNA] CTD PMID:19414516 NCBI chr12:15,826,864...15,885,423
Ensembl chr12:15,826,871...15,884,543
JBrowse link
G Fcgr2a Fc gamma receptor IIa multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FCGR3 mRNA] CTD PMID:19414516 NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
JBrowse link
G Fdx1 ferredoxin 1 multiple interactions
increases expression
ISO myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA] CTD PMID:28668616 NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414
JBrowse link
G Fig4 FIG4 phosphoinositide 5-phosphatase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FIG4 mRNA] CTD PMID:19414516 NCBI chr20:44,600,603...44,724,047
Ensembl chr20:44,600,603...44,723,844
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO [Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA
Cyclic AMP results in increased expression of FOS mRNA
CTD PMID:10064622 PMID:10711420 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Foxm1 forkhead box M1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA CTD PMID:33713149 NCBI chr 4:161,639,561...161,652,012
Ensembl chr 4:161,638,816...161,650,684
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA]
FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
CTD PMID:26847930 PMID:31953017 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Fshb follicle stimulating hormone subunit beta multiple interactions
increases abundance
increases secretion
EXP
ISO
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]
FSHB protein results in increased secretion of Cyclic AMP
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]
[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]
CTD PMID:8404651 PMID:18535249 PMID:23137853 PMID:23583632 PMID:25549949 More... NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
JBrowse link
G Fshr follicle stimulating hormone receptor multiple interactions ISO [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] CTD PMID:26895433 NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
JBrowse link
G Fzd10 frizzled class receptor 10 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA CTD PMID:33713149 NCBI chr12:28,098,371...28,101,566
Ensembl chr12:28,098,371...28,101,566
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions EXP
ISO
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]
[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]
CTD PMID:22676303 PMID:26847930 NCBI chr10:86,307,400...86,318,766 JBrowse link
G Gabpb1 GA binding protein transcription factor subunit beta 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GABPB1 mRNA] CTD PMID:19414516 NCBI chr 3:113,879,972...113,924,744
Ensembl chr 3:113,879,973...113,923,696
JBrowse link
G Gabra2 gamma-aminobutyric acid type A receptor subunit alpha 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA CTD PMID:33713149 NCBI chr14:37,096,995...37,230,030
Ensembl chr14:37,097,279...37,228,944
JBrowse link
G Gbp2 guanylate binding protein 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GBP2 mRNA] CTD PMID:19414516 NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
JBrowse link
G Gcg glucagon multiple interactions
increases chemical synthesis
increases abundance
ISO
EXP
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
GCG protein results in increased chemical synthesis of Cyclic AMP
Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP]
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP
CTD PMID:6312992 PMID:18669601 PMID:20074626 PMID:25191754 PMID:26964897 NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
JBrowse link
G Gdnf glial cell derived neurotrophic factor multiple interactions ISO 3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium] CTD PMID:19647008 PMID:33713149 NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA CTD PMID:33713149 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Ghrh growth hormone releasing hormone multiple interactions ISO [GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP CTD PMID:22308467 NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
JBrowse link
G Gip gastric inhibitory polypeptide multiple interactions ISO [GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP CTD PMID:25191754 NCBI chr10:80,968,410...80,976,506
Ensembl chr10:80,968,352...80,976,503
JBrowse link
G Gipr gastric inhibitory polypeptide receptor multiple interactions ISO [GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP CTD PMID:25191754 NCBI chr 1:78,804,287...78,814,462
Ensembl chr 1:78,805,593...78,814,462
JBrowse link
G Gli1 GLI family zinc finger 1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA CTD PMID:33713149 NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
JBrowse link
G Glipr2 GLI pathogenesis-related 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GLIPR2 mRNA] CTD PMID:19414516 NCBI chr 5:58,170,417...58,200,947
Ensembl chr 5:58,170,425...58,202,272
JBrowse link
G Glp1r glucagon-like peptide 1 receptor multiple interactions ISO [GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP
CTD PMID:18669601 PMID:25191754 NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241
JBrowse link
G Gnai2 G protein subunit alpha i2 multiple interactions ISO [[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:20713914 NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
JBrowse link
G Gnal G protein subunit alpha L multiple interactions ISO [[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP CTD PMID:15598656 NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599
JBrowse link
G Gnas GNAS complex locus multiple interactions ISO [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP]
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP
CTD PMID:11895442 PMID:15598656 PMID:23022524 NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262
JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions ISO [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP
[Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP
CTD PMID:17963371 PMID:23022524 NCBI chr 9:75,862,151...75,863,140
Ensembl chr 9:75,860,677...75,863,168
JBrowse link
G Gpc3 glypican 3 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GPC3 mRNA] CTD PMID:19414516 NCBI chr  X:131,868,983...132,236,837
Ensembl chr  X:131,868,990...132,236,798
JBrowse link
G Greb1l GREB1 like retinoic acid receptor coactivator multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GREB1L mRNA] CTD PMID:19414516 NCBI chr18:1,392,330...1,629,483
Ensembl chr18:1,392,725...1,628,067
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA CTD PMID:33713149 NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA CTD PMID:33713149 NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA CTD PMID:33713149 NCBI chr10:5,630,684...6,043,341
Ensembl chr10:5,631,369...6,044,637
JBrowse link
G Grin2b glutamate ionotropic receptor NMDA type subunit 2B multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA CTD PMID:33713149 NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions ISO [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein] CTD PMID:25191754 NCBI chr 1:201,581,480...201,601,580
Ensembl chr 1:201,581,480...201,601,582
JBrowse link
G Grn granulin precursor multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GRN mRNA] CTD PMID:19414516 NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO GSK3B protein affects the reaction [Deamino Arginine Vasopressin results in increased abundance of Cyclic AMP] CTD PMID:20056751 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G Gtpbp2 GTP binding protein 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GTPBP2 mRNA] CTD PMID:19414516 NCBI chr 9:14,813,964...14,823,419
Ensembl chr 9:14,813,964...14,823,241
JBrowse link
G Gypc glycophorin C (Gerbich blood group) multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GYPC mRNA] CTD PMID:19414516 NCBI chr18:24,160,738...24,193,408
Ensembl chr18:24,160,739...24,193,204
JBrowse link
G Hcar2 hydroxycarboxylic acid receptor 2 multiple interactions
decreases abundance
ISO [3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
[HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Cyclic AMP
CTD PMID:12563315 PMID:17124637 PMID:19223991 PMID:20655299 NCBI chr12:32,726,334...32,727,416
Ensembl chr12:32,726,184...32,728,504
JBrowse link
G Hdac2 histone deacetylase 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HDAC2 mRNA] CTD PMID:19414516 NCBI chr20:40,548,250...40,571,609
Ensembl chr20:40,548,250...40,571,609
JBrowse link
G Hdac6 histone deacetylase 6 affects abundance ISO HDAC6 protein affects the abundance of Cyclic AMP CTD PMID:28887310 NCBI chr  X:14,550,645...14,572,445
Ensembl chr  X:14,551,044...14,572,441
JBrowse link
G Hes3 hes family bHLH transcription factor 3 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA CTD PMID:33713149 NCBI chr 5:162,793,611...162,799,578
Ensembl chr 5:162,794,367...162,796,261
JBrowse link
G Hist2h2be histone cluster 2 H2B family member E multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIST2H2BE mRNA] CTD PMID:19414516 NCBI chr 2:183,780,449...183,783,030 JBrowse link
G Hivep2 HIVEP zinc finger 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIVEP2 mRNA] CTD PMID:19414516 NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993
JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha multiple interactions ISO Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter] CTD PMID:18602936 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
JBrowse link
G Hoxb1 homeo box B1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA CTD PMID:33713149 NCBI chr10:81,331,507...81,332,928
Ensembl chr10:81,331,507...81,332,836
JBrowse link
G Hp haptoglobin multiple interactions ISO Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA] CTD PMID:22117073 NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
JBrowse link
G Hrh1 histamine receptor H 1 multiple interactions ISO 1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]] CTD PMID:2419744 NCBI chr 4:147,564,781...147,649,353
Ensembl chr 4:147,645,995...147,647,455
JBrowse link
G Hrh2 histamine receptor H 2 increases abundance
multiple interactions
ISO HRH2 protein results in increased abundance of Cyclic AMP
[Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]
CTD PMID:9187264 PMID:9681472 PMID:15843518 NCBI chr17:10,368,355...10,407,791
Ensembl chr17:10,368,298...10,407,631
JBrowse link
G Hrh3 histamine receptor H3 multiple interactions EXP [imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:21276809 NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 increases expression ISO Cyclic AMP results in increased expression of HSD3B1 mRNA CTD PMID:25576683 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 increases expression ISO Cyclic AMP results in increased expression of HSD3B2 mRNA CTD PMID:18490834 NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A multiple interactions ISO [JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:11356925 PMID:20580787 NCBI chr 2:36,694,174...36,695,442
Ensembl chr 2:36,694,174...36,695,442
JBrowse link
G Htr1b 5-hydroxytryptamine receptor 1B multiple interactions ISO HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:11134654 NCBI chr 8:82,513,572...82,534,892
Ensembl chr 8:82,517,360...82,534,549
JBrowse link
G Htr6 5-hydroxytryptamine receptor 6 increases abundance
multiple interactions
ISO HTR6 protein results in increased abundance of Cyclic AMP
Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP]
CTD PMID:11406289 NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912
JBrowse link
G Htr7 5-hydroxytryptamine receptor 7 increases abundance
multiple interactions
ISO HTR7 results in increased abundance of Cyclic AMP
[3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]
CTD PMID:10720076 PMID:14578406 PMID:19509219 NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
JBrowse link
G Htra1 HtrA serine peptidase 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HTRA1 mRNA] CTD PMID:19414516 NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance
ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cyclic AMP] CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 multiple interactions ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein CTD PMID:32781018 NCBI chr16:67,430,684...67,442,459
Ensembl chr16:67,430,578...67,442,730
JBrowse link
G Ier3 immediate early response 3 multiple interactions
affects response to substance
EXP
ISO
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA]
IER3 protein affects the susceptibility to Cyclic AMP
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]]
CTD PMID:19414516 PMID:20713914 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
JBrowse link
G Ifng interferon gamma multiple interactions ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]] CTD PMID:32781018 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO 2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] CTD PMID:31953017 PMID:32446389 PMID:32781018 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA] CTD PMID:19414516 NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
JBrowse link
G Il12a interleukin 12A multiple interactions ISO Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein] CTD PMID:15843518 NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
JBrowse link
G Il12b interleukin 12B multiple interactions ISO Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein] CTD PMID:15843518 NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il15ra interleukin 15 receptor subunit alpha multiple interactions
decreases expression
ISO [Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA] CTD PMID:22117073 NCBI chr17:66,802,300...66,831,973
Ensembl chr17:66,802,334...66,832,278
JBrowse link
G Il17re interleukin 17 receptor E multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IL17RE mRNA] CTD PMID:19414516 NCBI chr 4:146,604,547...146,618,206
Ensembl chr 4:146,605,526...146,618,206
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases abundance
ISO 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]
CTD PMID:8904084 PMID:17709599 PMID:22117073 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il1rn interleukin 1 receptor antagonist multiple interactions
increases expression
ISO Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] CTD PMID:22117073 NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
JBrowse link
G Il4 interleukin 4 increases chemical synthesis
multiple interactions
ISO IL4 protein results in increased chemical synthesis of Cyclic AMP
Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP]
CTD PMID:12230500 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il6 interleukin 6 increases expression EXP Cyclic AMP analog results in increased expression of IL6 mRNA CTD PMID:10469353 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Inhba inhibin subunit beta A increases secretion ISO Cyclic AMP results in increased secretion of INHBA protein CTD PMID:20074812 NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
JBrowse link
G Inhbe inhibin subunit beta E multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA CTD PMID:33713149 NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IQGAP1 mRNA] CTD PMID:19414516 NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
JBrowse link
G Irf6 interferon regulatory factor 6 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IRF6 mRNA] CTD PMID:19414516 NCBI chr13:104,672,179...104,691,386
Ensembl chr13:104,672,179...104,691,386
JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ITGB1 mRNA] CTD PMID:19414516 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA CTD PMID:10711420 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA] CTD PMID:19414516 NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728
JBrowse link
G Kif15 kinesin family member 15 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KIF15 mRNA] CTD PMID:19414516 NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
JBrowse link
G Kng2 kininogen 2 increases abundance EXP KNG1 results in increased abundance of Cyclic AMP CTD PMID:15750287 NCBI chr11:77,913,876...77,936,247 JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LAMP1 mRNA] CTD PMID:19414516 NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
JBrowse link
G Lef1 lymphoid enhancer binding factor 1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA CTD PMID:33713149 NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
JBrowse link
G Lep leptin increases abundance
multiple interactions
increases expression
ISO LEP protein results in increased abundance of Cyclic AMP
3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA]
CTD PMID:11342529 PMID:27381457 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions
increases abundance
increases chemical synthesis
affects secretion
EXP
ISO
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]
LHB protein affects the secretion of Cyclic AMP
[LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; DDT inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]
CTD PMID:2153673 PMID:6430271 PMID:8404651 PMID:23071612 PMID:33638691 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor multiple interactions ISO [CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]
CTD PMID:19766106 PMID:20378682 NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
JBrowse link
G Lipe lipase E, hormone sensitive type increases activity ISO Cyclic AMP results in increased activity of LIPE protein CTD PMID:7155675 NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
JBrowse link
G Lmna lamin A/C multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LMNA mRNA] CTD PMID:19414516 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
JBrowse link
G LOC686683 similar to olfactory receptor 73 multiple interactions ISO [[Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP CTD PMID:12767924 PMID:15716417 NCBI chr 3:73,516,522...73,517,463 JBrowse link
G Lurap1l leucine rich adaptor protein 1-like multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LURAP1L mRNA] CTD PMID:19414516 NCBI chr 5:95,362,005...95,409,439
Ensembl chr 5:95,362,005...95,409,438
JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MAN1A mRNA] CTD PMID:19414516 NCBI chr20:33,202,509...33,385,747
Ensembl chr20:33,202,517...33,385,824
JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein CTD PMID:33713149 NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
JBrowse link
G Mc2r melanocortin 2 receptor multiple interactions ISO [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased expression of MC2R mRNA CTD PMID:23084589 NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488
JBrowse link
G Msantd3 Myb/SANT DNA binding domain containing 3 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MSANTD3 mRNA] CTD PMID:19414516 NCBI chr 5:62,866,022...62,892,444
Ensembl chr 5:62,866,022...62,888,859
JBrowse link
G Ndufb11 NADH:ubiquinone oxidoreductase subunit B11 increases phosphorylation
multiple interactions
ISO Cyclic AMP results in increased phosphorylation of NDUFB11 protein
Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]
CTD PMID:17904600 NCBI chr  X:1,572,805...1,575,063
Ensembl chr  X:1,572,785...1,575,062
JBrowse link
G Ngf nerve growth factor multiple interactions
increases expression
EXP [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA
Cyclic AMP results in increased expression of NGF mRNA
CTD PMID:2174743 PMID:2853697 NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
JBrowse link
G Nog noggin multiple interactions ISO NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] CTD PMID:23137853 NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
JBrowse link
G Npl N-acetylneuraminate pyruvate lyase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NPL mRNA] CTD PMID:19414516 NCBI chr13:65,655,099...65,697,464
Ensembl chr13:65,655,118...65,697,372
JBrowse link
G Nr0b1 nuclear receptor subfamily 0, group B, member 1 decreases expression
multiple interactions
ISO Cyclic AMP results in decreased expression of NR0B1 mRNA
Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA]
CTD PMID:19822634 NCBI chr  X:50,756,886...50,761,014
Ensembl chr  X:50,756,886...50,761,011
JBrowse link
G Ntan1 N-terminal asparagine amidase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NTAN1 mRNA] CTD PMID:19414516 NCBI chr10:2,111,085...2,126,123 JBrowse link
G Oat ornithine aminotransferase increases activity
multiple interactions
increases expression
EXP Cyclic AMP results in increased activity of OAT protein
Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]
CTD PMID:2824512 PMID:2827574 NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
JBrowse link
G Olr1646 olfactory receptor 1646 multiple interactions ISO [citronellal results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP
[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP; [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP
CTD PMID:15598656 NCBI chr15:27,733,881...27,734,825
Ensembl chr15:27,729,827...27,736,945
JBrowse link
G Olr72 olfactory receptor 72 multiple interactions ISO [pelargonic acid results in increased activity of OLFR586 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OLFR586 protein] which results in increased abundance of Cyclic AMP] CTD PMID:15598656 NCBI chr 1:157,454,391...157,455,398
Ensembl chr 1:157,454,041...157,456,953
JBrowse link
G Oprm1 opioid receptor, mu 1 multiple interactions ISO [7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP CTD PMID:11413242 NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
JBrowse link
G Os9 OS9, endoplasmic reticulum lectin multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of OS9 mRNA] CTD PMID:19414516 NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 increases expression
multiple interactions
EXP
ISO
Cyclic AMP results in increased expression of PCK1 mRNA
[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]
CTD PMID:2569870 PMID:8971075 PMID:10446394 PMID:22117073 PMID:22676303 More... NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
JBrowse link
G Pde10a phosphodiesterase 10A multiple interactions
increases hydrolysis
ISO Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP] CTD PMID:10373451 NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
JBrowse link
G Pde11a phosphodiesterase 11A increases hydrolysis ISO PDE11A protein results in increased hydrolysis of Cyclic AMP CTD PMID:10725373 NCBI chr 3:60,913,562...61,297,154 JBrowse link
G Pde4b phosphodiesterase 4B multiple interactions ISO [[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP
[Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein]
CTD PMID:16293762 PMID:21266552 PMID:21854221 NCBI chr 5:116,799,827...117,367,707
Ensembl chr 5:116,799,971...117,367,696
JBrowse link
G Pde7a phosphodiesterase 7A multiple interactions
increases hydrolysis
ISO 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP] CTD PMID:10618442 PMID:10814504 NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:101,718,444...101,806,681
JBrowse link
G Pde7b phosphodiesterase 7B increases hydrolysis
multiple interactions
ISO PDE7B protein results in increased hydrolysis of Cyclic AMP
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]
CTD PMID:10618442 PMID:10814504 PMID:10872825 NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:15,182,704...15,492,900
JBrowse link
G Pde8a phosphodiesterase 8A multiple interactions
increases metabolic processing
increases hydrolysis
ISO Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]
PDE8A protein results in increased hydrolysis of Cyclic AMP
Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP]
CTD PMID:9671792 PMID:12681444 NCBI chr 1:135,166,143...135,288,986
Ensembl chr 1:135,166,237...135,288,024
JBrowse link
G Pde8b phosphodiesterase 8B multiple interactions
increases metabolic processing
increases hydrolysis
ISO 9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP] CTD PMID:9784418 PMID:12681444 NCBI chr 2:26,275,117...26,479,725
Ensembl chr 2:26,276,635...26,509,209
JBrowse link
G Pde9a phosphodiesterase 9A increases hydrolysis ISO PDE9A protein results in increased hydrolysis of Cyclic AMP CTD PMID:9624146 NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948
JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions
affects abundance
ISO 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP] CTD PMID:28887310 NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
JBrowse link
G Pebp1 phosphatidylethanolamine binding protein 1 multiple interactions ISO PEBP1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] CTD PMID:26670611 NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
JBrowse link
G Pfn2 profilin 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PFN2 mRNA] CTD PMID:19414516 NCBI chr 2:142,067,102...142,072,938
Ensembl chr 2:142,067,104...142,072,938
JBrowse link
G Pkia cAMP-dependent protein kinase inhibitor alpha multiple interactions ISO [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein] CTD PMID:29669941 NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282
JBrowse link
G Pla2g4a phospholipase A2 group IVA increases expression
multiple interactions
EXP Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein]
CTD PMID:22187434 NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
JBrowse link
G Pomc proopiomelanocortin multiple interactions
increases abundance
EXP
ISO
[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP]
POMC protein modified form results in increased abundance of Cyclic AMP
Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP]
CTD PMID:4306506 PMID:26586997 NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
JBrowse link
G Por cytochrome p450 oxidoreductase increases expression ISO Cyclic AMP results in increased expression of POR mRNA CTD PMID:25576683 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions
increases expression
ISO
EXP
Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]
Cyclic AMP results in increased expression of PPARGC1A mRNA
CTD PMID:18602936 PMID:22117073 PMID:22676303 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Ppp1r14b protein phosphatase 1, regulatory (inhibitor) subunit 14B multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PPP1R14B mRNA] CTD PMID:19414516 NCBI chr 1:204,165,210...204,167,320
Ensembl chr 1:204,163,299...204,167,319
JBrowse link
G Prkacb protein kinase cAMP-activated catalytic subunit beta multiple interactions
affects response to substance
ISO [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] CTD PMID:29669941 NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
JBrowse link
G Prkar1a protein kinase cAMP-dependent type I regulatory subunit alpha multiple interactions ISO [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] CTD PMID:29669941 NCBI chr10:94,621,042...94,639,534
Ensembl chr10:94,620,039...94,639,041
JBrowse link
G Prkar2a protein kinase cAMP-dependent type II regulatory subunit alpha multiple interactions EXP Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] CTD PMID:11907174 NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
JBrowse link
G Prkar2b protein kinase cAMP-dependent type II regulatory subunit beta multiple interactions EXP Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] CTD PMID:11907174 NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
JBrowse link
G Prl prolactin multiple interactions
increases secretion
EXP
ISO
[Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]
Cyclic AMP results in increased secretion of PRL protein
CTD PMID:20074812 PMID:23022511 PMID:31953017 PMID:32446389 PMID:32781018 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
JBrowse link
G Prok1 prokineticin 1 affects response to substance ISO PROK1 protein affects the susceptibility to Cyclic AMP CTD PMID:21546446 NCBI chr 2:194,853,991...194,859,250
Ensembl chr 2:194,853,991...194,859,250
JBrowse link
G Ptgdr2 prostaglandin D2 receptor 2 multiple interactions ISO [5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP CTD PMID:15563582 NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
JBrowse link
G Ptger2 prostaglandin E receptor 2 multiple interactions ISO [Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP] CTD PMID:23526216 NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
JBrowse link
G Ptger3 prostaglandin E receptor 3 multiple interactions ISO [Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP CTD PMID:10357836 NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434
JBrowse link
G Ptger4 prostaglandin E receptor 4 multiple interactions ISO [Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP] CTD PMID:23526216 NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
JBrowse link
G Ptgir prostaglandin I2 receptor multiple interactions ISO [cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] CTD PMID:11895442 NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:77,579,596...77,581,979
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions EXP [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP] CTD PMID:21873648 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pth parathyroid hormone increases abundance EXP PTH protein results in increased abundance of Cyclic AMP CTD PMID:26851681 NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
JBrowse link
G Pthlh parathyroid hormone-like hormone increases abundance ISO PTHLH protein results in increased abundance of Cyclic AMP CTD PMID:10600786 NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
JBrowse link
G Ptma prothymosin alpha increases abundance ISO PTMA protein results in increased abundance of Cyclic AMP CTD PMID:9147362 NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333
JBrowse link
G Rab3b RAB3B, member RAS oncogene family multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RAB3B mRNA] CTD PMID:19414516 NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
JBrowse link
G Rap1a RAP1A, member of RAS oncogene family increases activity ISO Cyclic AMP results in increased activity of RAP1A protein CTD PMID:24701590 NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
JBrowse link
G Rap1b RAP1B, member of RAS oncogene family multiple interactions EXP
ISO
[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] CTD PMID:21693435 NCBI chr 7:53,423,039...53,456,388
Ensembl chr 7:53,423,130...53,456,370
JBrowse link
G Rbfox3 RNA binding fox-1 homolog 3 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein CTD PMID:33713149 NCBI chr10:103,720,355...104,157,277
Ensembl chr10:103,720,636...104,156,935
JBrowse link
G Rbm12 RNA binding motif protein 12 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RBM12 mRNA] CTD PMID:19414516 NCBI chr 3:144,587,548...144,629,950
Ensembl chr 3:144,611,623...144,629,915
JBrowse link
G RGD1310587 similar to hypothetical protein FLJ14146 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGD1310587 mRNA] CTD PMID:19414516 NCBI chr13:96,422,308...96,432,044
Ensembl chr13:96,422,302...96,432,068
JBrowse link
G Rgl1 ral guanine nucleotide dissociation stimulator,-like 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGL1 mRNA] CTD PMID:19414516 NCBI chr13:64,634,489...64,904,170
Ensembl chr13:64,635,246...64,904,191
JBrowse link
G Rmdn3 regulator of microtubule dynamics 3 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RMDN3 mRNA] CTD PMID:19414516 NCBI chr 3:106,125,961...106,146,568
Ensembl chr 3:106,125,951...106,146,586
JBrowse link
G S100b S100 calcium binding protein B multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein CTD PMID:33713149 NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
JBrowse link
G Scn2a sodium voltage-gated channel alpha subunit 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA CTD PMID:33713149 NCBI chr 3:50,302,781...50,437,504
Ensembl chr 3:50,302,877...50,437,214
JBrowse link
G Sct secretin multiple interactions
increases abundance
EXP Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP] CTD PMID:6312992 NCBI chr 1:196,382,941...196,383,635
Ensembl chr 1:196,382,856...196,383,658
JBrowse link
G Sdc1 syndecan 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SDC1 mRNA] CTD PMID:19414516 NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
JBrowse link
G Slc17a6 solute carrier family 17 member 6 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA CTD PMID:33713149 NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
JBrowse link
G Slc17a7 solute carrier family 17 member 7 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein CTD PMID:33713149 NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588
JBrowse link
G Slc22a8 solute carrier family 22 member 8 affects transport ISO SLC22A8 protein affects the transport of Cyclic AMP CTD PMID:11306713 NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
JBrowse link
G Slc2a5 solute carrier family 2 member 5 affects expression
multiple interactions
ISO
EXP
Cyclic AMP affects the expression of SLC2A5 mRNA
[[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein
[Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA
CTD PMID:8037665 PMID:8554516 PMID:12820898 NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
JBrowse link
G Slc4a2 solute carrier family 4 member 2 multiple interactions EXP Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates] CTD PMID:12612912 NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
JBrowse link
G Smoc2 SPARC related modular calcium binding 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SMOC2 mRNA] CTD PMID:19414516 NCBI chr 1:55,262,472...55,391,804
Ensembl chr 1:55,262,530...55,391,693
JBrowse link
G Snx33 sorting nexin 33 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SNX33 mRNA] CTD PMID:19414516 NCBI chr 8:57,315,861...57,328,522
Ensembl chr 8:57,317,161...57,327,538
JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions ISO 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] CTD PMID:23782265 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] CTD PMID:20685861 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Srd5a1 steroid 5 alpha-reductase 1 increases expression ISO Cyclic AMP results in increased expression of SRD5A1 mRNA CTD PMID:25576683 NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
JBrowse link
G Sst somatostatin multiple interactions ISO [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] CTD PMID:22056254 NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
JBrowse link
G Sstr2 somatostatin receptor 2 multiple interactions ISO [64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] CTD PMID:22056254 NCBI chr10:98,664,204...98,671,370
Ensembl chr10:98,664,216...98,674,351
JBrowse link
G St6gal2 ST6 beta-galactoside alpha-2,6-sialyltransferase 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ST6GAL2 mRNA] CTD PMID:19414516 NCBI chr 9:9,181,744...9,274,161
Ensembl chr 9:9,182,399...9,269,697
JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions
increases expression
ISO [Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein]
Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein
CTD PMID:19822634 PMID:20100736 PMID:25576683 PMID:28668616 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
JBrowse link
G Taar1 trace-amine-associated receptor 1 multiple interactions ISO [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
[3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
CTD PMID:19725810 NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084
JBrowse link
G Tas1r2 taste 1 receptor member 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAS1R2 mRNA] CTD PMID:19414516 NCBI chr 5:151,909,648...151,925,345 JBrowse link
G Tax1bp1 Tax1 binding protein 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAX1BP1 mRNA] CTD PMID:19414516 NCBI chr 4:81,821,991...81,877,906
Ensembl chr 4:81,821,989...81,879,100
JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase multiple interactions ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA CTD PMID:32781018 NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA CTD PMID:33713149 NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
JBrowse link
G Tex14 testis expressed 14, intercellular bridge forming factor multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TEX14 mRNA] CTD PMID:19414516 NCBI chr10:72,231,766...72,356,938
Ensembl chr10:72,231,801...72,355,805
JBrowse link
G Tff1 trefoil factor 1 multiple interactions
increases expression
ISO CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] CTD PMID:20360387 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
G Tgfb3 transforming growth factor, beta 3 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
JBrowse link
G Tmsb15b2 thymosin beta 15B2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMSB15B2 mRNA] CTD PMID:19414516 NCBI chr  X:100,298,705...100,300,820
Ensembl chr  X:100,298,514...100,300,886
JBrowse link
G Tmtc4 transmembrane O-mannosyltransferase targeting cadherins 4 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMTC4 mRNA] CTD PMID:19414516 NCBI chr15:100,000,157...100,056,573
Ensembl chr15:100,000,152...100,056,543
JBrowse link
G Tnf tumor necrosis factor decreases expression
multiple interactions
ISO Cyclic AMP results in decreased expression of TNF protein
Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
CTD PMID:8550079 PMID:21266552 PMID:23566200 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfsf12 TNF superfamily member 12 decreases expression ISO Cyclic AMP results in decreased expression of TNFSF12 mRNA CTD PMID:22117073 NCBI chr10:54,403,870...54,413,213
Ensembl chr10:54,403,870...54,413,213
JBrowse link
G Trpv4 transient receptor potential cation channel, subfamily V, member 4 increases expression
multiple interactions
EXP Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein]
CTD PMID:22187434 NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
JBrowse link
G Tshb thyroid stimulating hormone subunit beta multiple interactions
increases abundance
ISO [Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] CTD PMID:19766106 PMID:21072367 PMID:21123444 NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
JBrowse link
G Tshr thyroid stimulating hormone receptor multiple interactions
increases abundance
ISO [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] CTD PMID:19766106 PMID:21123444 NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
JBrowse link
G Ttc6 tetratricopeptide repeat domain 6 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TTC6 mRNA] CTD PMID:19414516 NCBI chr 6:75,136,827...75,368,176
Ensembl chr 6:75,136,792...75,368,178
JBrowse link
G Tubb3 tubulin, beta 3 class III multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
JBrowse link
G Uba5 ubiquitin-like modifier activating enzyme 5 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of UBA5 mRNA] CTD PMID:19414516 NCBI chr 8:104,665,241...104,680,850
Ensembl chr 8:104,665,046...104,680,894
JBrowse link
G Vash1 vasohibin 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH1 mRNA] CTD PMID:19414516 NCBI chr 6:106,330,374...106,345,740
Ensembl chr 6:106,329,123...106,345,726
JBrowse link
G Vash2 vasohibin 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH2 mRNA] CTD PMID:19414516 NCBI chr13:102,529,715...102,561,204
Ensembl chr13:102,529,719...102,560,391
JBrowse link
G Vat1 vesicle amine transport 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VAT1 mRNA] CTD PMID:19414516 NCBI chr10:86,389,549...86,397,167
Ensembl chr10:86,389,545...86,397,224
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA] CTD PMID:10788502 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vip vasoactive intestinal peptide multiple interactions
increases abundance
ISO
EXP
[VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP
alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]
VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP
CTD PMID:1657658 PMID:2467674 PMID:7733904 PMID:20732086 NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216
JBrowse link
G Vipr2 vasoactive intestinal peptide receptor 2 multiple interactions ISO [ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:7733904 NCBI chr 6:136,996,664...137,070,599
Ensembl chr 6:137,001,511...137,070,597
JBrowse link
G Wnt5a Wnt family member 5A multiple interactions ISO WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] CTD PMID:20685861 NCBI chr16:3,695,667...3,718,234
Ensembl chr16:3,697,032...3,718,234
JBrowse link
G Zfp36l2 zinc finger protein 36, C3H type-like 2 increases abundance ISO ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP CTD PMID:24830504 NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064
JBrowse link
3',5'-cyclic GMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc4 ATP binding cassette subfamily C member 4 increases export
increases transport
multiple interactions
ISO ABCC4 protein results in increased export of Cyclic GMP
ABCC4 protein results in increased transport of Cyclic GMP
daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]
CTD PMID:11856762 PMID:16156793 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
JBrowse link
G Agt angiotensinogen multiple interactions
increases abundance
EXP AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; AGT protein modified form inhibits the reaction [Streptozocin results in decreased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]]
AGT protein modified form results in increased abundance of Cyclic GMP
CTD PMID:11696475 PMID:28299329 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Agtr2 angiotensin II receptor, type 2 multiple interactions EXP [PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr  X:112,119,673...112,124,060
Ensembl chr  X:112,120,228...112,124,057
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Cyclic GMP] CTD PMID:12891555 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions ISO ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP] CTD PMID:17585900 NCBI chr12:34,949,549...34,982,527 JBrowse link
G Apoe apolipoprotein E decreases abundance ISO APOE gene mutant form results in decreased abundance of Cyclic GMP CTD PMID:11397713 NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
JBrowse link
G Bdkrb1 bradykinin receptor B1 multiple interactions EXP [bradykinin, Leu(8)-des-Arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
JBrowse link
G Bdkrb2 bradykinin receptor B2 multiple interactions EXP [icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
JBrowse link
G Casp3 caspase 3 multiple interactions EXP Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein] CTD PMID:9388267 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] CTD PMID:25490417 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cct7 chaperonin containing TCP1 subunit 7 multiple interactions ISO CCT7 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] CTD PMID:24213632 NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
JBrowse link
G Edn1 endothelin 1 multiple interactions
increases abundance
EXP Puromycin Aminonucleoside inhibits the reaction [EDN1 protein results in increased abundance of Cyclic GMP] CTD PMID:12972712 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Edn3 endothelin 3 multiple interactions
increases abundance
EXP Puromycin Aminonucleoside promotes the reaction [EDN3 protein results in increased abundance of Cyclic GMP] CTD PMID:12972712 NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
JBrowse link
G Epo erythropoietin multiple interactions ISO EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP] CTD PMID:25041251 PMID:25490417 NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
JBrowse link
G Gch1 GTP cyclohydrolase 1 affects abundance
increases abundance
multiple interactions
ISO GCH1 protein affects the abundance of Cyclic GMP
GCH1 gene mutant form results in increased abundance of Cyclic GMP
CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]
CTD PMID:21963838 PMID:25490417 NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
JBrowse link
G Gnrh1 gonadotropin releasing hormone 1 multiple interactions EXP [manganese chloride results in increased chemical synthesis of Cyclic GMP] which results in increased secretion of GNRH1 protein CTD PMID:17110411 PMID:17290048 NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581
JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions
increases abundance
ISO [GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP; GUCY1A1 protein mutant form inhibits the reaction [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased abundance of Cyclic GMP]; GUCY1A1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP]
GUCY1A1 gene mutant form results in increased abundance of Cyclic GMP
CTD PMID:22171090 PMID:24213632 PMID:25373139 NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
JBrowse link
G Gucy1b1 guanylate cyclase 1 soluble subunit beta 1 multiple interactions ISO [GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP CTD PMID:22171090 NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
JBrowse link
G Hmox2 heme oxygenase 2 affects abundance ISO HMOX2 affects the abundance of Cyclic GMP CTD PMID:16181104 NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
JBrowse link
G Il12rb2 interleukin 12 receptor subunit beta 2 increases expression ISO Cyclic GMP results in increased expression of IL12RB2 mRNA CTD PMID:12451176 NCBI chr 4:96,424,615...96,515,327
Ensembl chr 4:96,426,842...96,515,289
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases abundance
EXP
ISO
Halothane inhibits the reaction [IL1B protein results in increased abundance of Cyclic GMP]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP]
CTD PMID:11506125 PMID:14762100 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions
decreases phosphorylation
ISO Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]
Cyclic GMP results in decreased phosphorylation of MAP2K1 protein
CTD PMID:18225537 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 decreases phosphorylation
multiple interactions
ISO Cyclic GMP results in decreased phosphorylation of MAP2K2 protein
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]
CTD PMID:18225537 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases activity ISO Cyclic GMP analog results in increased activity of MAPK8 protein CTD PMID:11051267 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP [testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Cyclic GMP CTD PMID:20463352 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions
increases abundance
ISO
EXP
NOS3 protein affects the reaction [Ramipril results in increased abundance of Cyclic GMP]
NOS3 protein results in increased abundance of Cyclic GMP
CTD PMID:11504159 PMID:16891913 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
JBrowse link
G Nppa natriuretic peptide A multiple interactions
increases abundance
ISO
EXP
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]; Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]
NPPA protein results in increased abundance of Cyclic GMP
AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]; Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]]
CTD PMID:9421401 PMID:11696475 PMID:12022755 PMID:12582005 PMID:12972712 More... NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
JBrowse link
G Nppc natriuretic peptide C increases chemical synthesis
increases abundance
multiple interactions
EXP NPPC protein results in increased chemical synthesis of Cyclic GMP
NPPC protein results in increased abundance of Cyclic GMP
Ammonia inhibits the reaction [NPPC protein results in increased chemical synthesis of Cyclic GMP]; Fluoroacetates inhibits the reaction [NPPC protein results in increased abundance of Cyclic GMP]
CTD PMID:17629948 PMID:18222015 NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251
JBrowse link
G Pde10a phosphodiesterase 10A multiple interactions
increases hydrolysis
ISO Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] CTD PMID:10373451 NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
JBrowse link
G Pde11a phosphodiesterase 11A multiple interactions
increases hydrolysis
ISO 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] CTD PMID:10725373 NCBI chr 3:60,913,562...61,297,154 JBrowse link
G Pde1a phosphodiesterase 1A multiple interactions EXP PDE1A protein inhibits the reaction [Nitroglycerin results in increased abundance of Cyclic GMP] CTD PMID:11696475 NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
JBrowse link
G Pde5a phosphodiesterase 5A decreases abundance ISO PDE5A protein results in decreased abundance of Cyclic GMP CTD PMID:10422958 NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
JBrowse link
G Pde9a phosphodiesterase 9A increases hydrolysis
multiple interactions
ISO PDE9A protein results in increased hydrolysis of Cyclic GMP
zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP]
CTD PMID:9624146 NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948
JBrowse link
G Pomc proopiomelanocortin affects abundance EXP POMC protein affects the abundance of Cyclic GMP CTD PMID:11193135 NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
JBrowse link
G Ptpn12 protein tyrosine phosphatase, non-receptor type 12 increases activity EXP Cyclic GMP results in increased activity of PTPN12 protein CTD PMID:12714323 NCBI chr 4:14,020,997...14,092,931
Ensembl chr 4:14,021,052...14,092,927
JBrowse link
G Stk11 serine/threonine kinase 11 multiple interactions ISO STK11 protein promotes the reaction [Histamine results in increased abundance of Cyclic GMP] CTD PMID:21145922 NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases abundance
EXP 7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; KMUP 1 inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; zaprinast inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP] CTD PMID:16754782 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
increases abundance
ISO N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [VEGFA protein results in increased abundance of Cyclic GMP] CTD PMID:18575783 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vim vimentin multiple interactions ISO VIM protein affects the susceptibility to [Acetylcholine co-treated with Cyclic GMP co-treated with Indomethacin] CTD PMID:11588525 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions EXP [Xanthine co-treated with XDH protein] inhibits the reaction [Nitroprusside results in increased abundance of Cyclic GMP] CTD PMID:17339839 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
JBrowse link
3'-CMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdipt CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions ISO [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408
JBrowse link
3'-phospho-5'-adenylyl sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G P2ry1 purinergic receptor P2Y1 decreases activity ISO Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein CTD PMID:22273509 NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions
increases sulfation
ISO 2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]
SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate
CTD PMID:11425650 PMID:16601080 PMID:20545351 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] CTD PMID:15483193 NCBI chr 1:75,451,178...75,508,142 JBrowse link
3-iodobenzyl-5'-N-methylcarboxamidoadenosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adora3 adenosine A3 receptor multiple interactions EXP
ISO
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]]; 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]
[N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Dizocilpine Maleate; [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Scopolamine; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein
CTD PMID:12672554 PMID:15452191 PMID:19966059
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein] CTD PMID:16116186 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
decreases response to substance
ISO N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of BIRC3 mRNA
BIRC3 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
CTD PMID:16088125 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases response to substance ISO BIRC5 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine CTD PMID:16088125 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA] CTD PMID:15452191 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Il12a interleukin 12A multiple interactions ISO N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] CTD PMID:16116186 NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
JBrowse link
G Il12b interleukin 12B multiple interactions ISO N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; Wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] CTD PMID:16116186 NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 decreases response to substance
decreases expression
ISO NAIP protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of NAIP mRNA
CTD PMID:16088125 NCBI chr 2:31,507,423...31,559,098 JBrowse link
G Nppa natriuretic peptide A multiple interactions EXP 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] CTD PMID:15452191 PMID:19966059 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
JBrowse link
G Rgs2 regulator of G-protein signaling 2 multiple interactions EXP N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA] CTD PMID:15452191 NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
JBrowse link
G Slc9a1 solute carrier family 9 member A1 multiple interactions EXP N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein] CTD PMID:15452191 NCBI chr 5:145,576,341...145,629,630
Ensembl chr 5:145,576,334...145,629,624
JBrowse link
5'-S-methyl-5'-thioadenosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation
multiple interactions
ISO 5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein
IL7 protein inhibits the reaction [5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein]
CTD PMID:31712395 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression ISO 5'-methylthioadenosine results in decreased expression of COL1A1 mRNA CTD PMID:15983038 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col1a2 collagen type I alpha 2 chain decreases expression ISO 5'-methylthioadenosine results in decreased expression of COL1A2 mRNA CTD PMID:15983038 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine]
CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Ifng interferon gamma multiple interactions
decreases secretion
ISO 5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IFNG mRNA]
5'-methylthioadenosine results in decreased secretion of IFNG protein
CTD PMID:17080400 PMID:31712395 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA] CTD PMID:17080400 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions
decreases secretion
ISO 5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL2 mRNA]
5'-methylthioadenosine results in decreased secretion of IL2 protein
CTD PMID:17080400 PMID:31712395 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 multiple interactions ISO 5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA] CTD PMID:17080400 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Il7 interleukin 7 multiple interactions ISO IL7 protein inhibits the reaction [5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein] CTD PMID:31712395 NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075
JBrowse link
G Ltb lymphotoxin beta multiple interactions ISO 5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of LTB mRNA] CTD PMID:17080400 NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
JBrowse link
G Mdm4 MDM4 regulator of p53 multiple interactions ISO 5'-methylthioadenosine affects the splicing of and affects the expression of MDM4 mRNA alternative form CTD PMID:31712395 NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO 5'-methylthioadenosine results in decreased phosphorylation of MTOR protein CTD PMID:31712395 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO 5'-methylthioadenosine results in decreased phosphorylation of RPS6 protein CTD PMID:31712395 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Tp53 tumor protein p53 increases expression ISO 5'-methylthioadenosine results in increased expression of TP53 protein CTD PMID:31712395 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
5-azacytidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] CTD PMID:22841775 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 decreases expression ISO Azacitidine results in decreased expression of ADAMTS1 mRNA CTD PMID:20823114 NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
JBrowse link
G Adrb1 adrenoceptor beta 1 affects expression ISO Azacitidine affects the expression of ADRB1 mRNA CTD PMID:19002953 NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
JBrowse link
G Adrb2 adrenoceptor beta 2 affects expression
multiple interactions
ISO Azacitidine affects the expression of ADRB2 mRNA
Azacitidine inhibits the reaction [Particulate Matter results in decreased expression of ADRB2 mRNA]
CTD PMID:19002953 PMID:30986742 NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
JBrowse link
G Afp alpha-fetoprotein increases expression ISO Azacitidine results in increased expression of AFP mRNA CTD PMID:27590069 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Aggf1 angiogenic factor with G patch and FHA domains 1 increases expression ISO Azacitidine results in increased expression of AGGF1 mRNA CTD PMID:19194470 NCBI chr 2:26,619,336...26,646,050
Ensembl chr 2:26,619,339...26,645,952
JBrowse link
G Ahr aryl hydrocarbon receptor increases expression
multiple interactions
ISO Azacitidine results in increased expression of AHR mRNA
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]
CTD PMID:12927368 PMID:17682057 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Ak5 adenylate kinase 5 increases expression ISO Azacitidine results in increased expression of AK5 mRNA CTD PMID:20823114 NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] CTD PMID:22841775 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Alad aminolevulinate dehydratase decreases expression ISO Azacitidine results in decreased expression of ALAD mRNA CTD PMID:19194470 NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
JBrowse link
G Alb albumin decreases expression
increases expression
ISO Azacitidine results in decreased expression of ALB protein
Azacitidine results in increased expression of ALB mRNA
CTD PMID:27590069 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions ISO [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]] CTD PMID:17682057 NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
JBrowse link
G Anxa1 annexin A1 decreases expression EXP Azacitidine results in decreased expression of ANXA1 protein CTD PMID:17105402 NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
JBrowse link
G App amyloid beta precursor protein decreases methylation
multiple interactions
ISO Azacitidine results in decreased methylation of APP promoter
Azacitidine results in increased expression of and results in increased cleavage of APP protein; Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]
CTD PMID:19635394 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Aqp5 aquaporin 5 decreases methylation
increases expression
multiple interactions
ISO Azacitidine results in decreased methylation of AQP5 promoter
Azacitidine results in increased expression of AQP5 protein
[Azacitidine results in decreased methylation of AQP5 promoter] which results in increased expression of AQP5 mRNA; Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter]
CTD PMID:17198683 NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
JBrowse link
G Aqp9 aquaporin 9 multiple interactions
increases expression
ISO [Azacitidine results in increased expression of AQP9 mRNA] which results in increased uptake of arsenic trioxide; HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA] CTD PMID:25953102 NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
JBrowse link
G Ar androgen receptor multiple interactions
increases expression
ISO [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to Dihydrotestosterone CTD PMID:18324645 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Arhgap35 Rho GTPase activating protein 35 increases expression ISO Azacitidine results in increased expression of ARHGAP35 mRNA CTD PMID:20823114 NCBI chr 1:77,202,436...77,319,298
Ensembl chr 1:77,202,436...77,319,298
JBrowse link
G Arhgef2 Rho/Rac guanine nucleotide exchange factor 2 decreases expression ISO Azacitidine results in decreased expression of ARHGEF2 mRNA CTD PMID:20823114 NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
JBrowse link
G Art1 ADP-ribosyltransferase 1 increases expression ISO Azacitidine results in increased expression of ART1 mRNA CTD PMID:20823114 NCBI chr 1:156,478,096...156,487,172
Ensembl chr 1:156,482,621...156,487,172
JBrowse link
G Asb2 ankyrin repeat and SOCS box-containing 2 increases expression ISO Azacitidine results in increased expression of ASB2 mRNA CTD PMID:20823114 NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854
JBrowse link
G Atp2b1 ATPase plasma membrane Ca2+ transporting 1 decreases expression ISO Azacitidine results in decreased expression of ATP2B1 mRNA CTD PMID:20823114 NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
JBrowse link
G Atp6v0c ATPase H+ transporting V0 subunit C increases expression ISO Azacitidine results in increased expression of ATP6V0C mRNA CTD PMID:20823114 NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
JBrowse link
G Aurka aurora kinase A multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of AURKA mRNA CTD PMID:18720364 NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
JBrowse link
G Bad BCL2-associated agonist of cell death increases expression
multiple interactions
EXP Azacitidine results in increased expression of BAD mRNA
[Azacitidine co-treated with entinostat] results in increased expression of BAD mRNA
CTD PMID:21224363 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression
EXP [Azacitidine co-treated with entinostat] results in increased expression of BAK1 mRNA
Azacitidine results in increased expression of BAK1 mRNA
CTD PMID:21224363 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO Bleomycin inhibits the reaction [Azacitidine results in increased expression of BAX mRNA] CTD PMID:32278510 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcat1 branched chain amino acid transaminase 1 decreases expression ISO Azacitidine results in decreased expression of BCAT1 mRNA CTD PMID:20823114 NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 mRNA]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 protein]
Azacitidine results in decreased expression of BCL2 mRNA; Azacitidine results in decreased expression of BCL2 protein
CTD PMID:32278510 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
affects expression
ISO [metacept-1 co-treated with Azacitidine] results in decreased expression of BCL2L1
[Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein
CTD PMID:18443271 PMID:19148494 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l13 BCL2 like 13 increases expression ISO Azacitidine results in increased expression of BCL2L13 mRNA CTD PMID:20823114 NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
JBrowse link
G Bdnf brain-derived neurotrophic factor increases expression
decreases methylation
multiple interactions
ISO Azacitidine results in increased expression of BDNF mRNA
Azacitidine results in decreased methylation of BDNF promoter
Tetrodotoxin inhibits the reaction [Azacitidine results in decreased methylation of BDNF promoter]; Tetrodotoxin inhibits the reaction [Azacitidine results in increased expression of BDNF mRNA]
CTD PMID:18184782 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Bglap bone gamma-carboxyglutamate protein decreases expression EXP Azacitidine results in decreased expression of BGLAP protein CTD PMID:18037191 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Bicd1 BICD cargo adaptor 1 decreases expression ISO Azacitidine results in decreased expression of BICD1 mRNA CTD PMID:20823114 NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434
JBrowse link
G Bik BCL2-interacting killer multiple interactions
increases expression
EXP [Azacitidine co-treated with entinostat] results in increased expression of BIK mRNA
Azacitidine results in increased expression of BIK mRNA
CTD PMID:21224363 NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
JBrowse link
G Bmp15 bone morphogenetic protein 15 increases expression ISO Azacitidine results in increased expression of BMP15 mRNA CTD PMID:23395740 NCBI chr  X:16,169,123...16,174,187
Ensembl chr  X:16,169,123...16,174,187
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO Azacitidine results in increased expression of BNIP3 mRNA CTD PMID:25446377 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
JBrowse link
G Bok BCL2 family apoptosis regulator BOK multiple interactions
increases expression
EXP [Azacitidine co-treated with entinostat] results in increased expression of BOK mRNA
Azacitidine results in increased expression of BOK mRNA
CTD PMID:21224363 NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
JBrowse link
G Bub1b BUB1 mitotic checkpoint serine/threonine kinase B multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of BUB1B mRNA CTD PMID:18720364 NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
JBrowse link
G C3ar1 complement C3a receptor 1 increases expression ISO Azacitidine results in increased expression of C3AR1 mRNA CTD PMID:19194470 NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
JBrowse link
G Calca calcitonin-related polypeptide alpha decreases methylation ISO Azacitidine results in decreased methylation of CALCA promoter CTD PMID:19299654 NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
JBrowse link
G Cald1 caldesmon 1 increases expression ISO Azacitidine results in increased expression of CALD1 mRNA CTD PMID:20823114 NCBI chr 4:63,265,781...63,446,936
Ensembl chr 4:63,265,942...63,446,932
JBrowse link
G Casp3 caspase 3 affects expression
increases expression
multiple interactions
ISO Azacitidine affects the expression of CASP3 protein
Azacitidine results in increased expression of CASP3 mRNA
[metacept-1 co-treated with Azacitidine] results in increased expression of CASP3
CTD PMID:18443271 PMID:19148494 PMID:23395740 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 increases expression ISO Azacitidine results in increased expression of CASP8 mRNA CTD PMID:18082045 PMID:23395740 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 increases expression ISO Azacitidine results in increased expression of CASP9 mRNA CTD PMID:23395740 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccna1 cyclin A1 multiple interactions
decreases expression
ISO Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]; Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; Azacitidine promotes the reaction [H4-16 protein modified form binds to CCNA1 promoter]
Azacitidine results in decreased expression of CCNA1 mRNA
CTD PMID:17698632 NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
JBrowse link
G Ccna2 cyclin A2 multiple interactions
decreases expression
ISO [Azacitidine co-treated with Thalidomide] affects the expression of CCNA2 mRNA
Azacitidine results in decreased expression of CCNA2 mRNA
CTD PMID:18720364 PMID:20823114 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnb1 cyclin B1 multiple interactions
increases expression
ISO [Azacitidine co-treated with Thalidomide] affects the expression of CCNB1 mRNA
Azacitidine results in increased expression of CCNB1 protein
CTD PMID:18720364 PMID:20607034 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd1 cyclin D1 increases expression ISO Azacitidine results in increased expression of CCND1 mRNA CTD PMID:20823114 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd2 cyclin D2 affects methylation
multiple interactions
ISO Azacitidine affects the methylation of CCND2 promoter
[Azacitidine affects the methylation of CCND2 promoter] which affects the expression of CCND2 mRNA
CTD PMID:17016690 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Ccng2 cyclin G2 decreases expression ISO Azacitidine results in decreased expression of CCNG2 mRNA CTD PMID:21245298 NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
JBrowse link
G Cd274 CD274 molecule multiple interactions ISO Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]] CTD PMID:32894642 NCBI chr 1:227,116,627...227,137,379
Ensembl chr 1:227,116,649...227,134,450
JBrowse link
G Cdc20 cell division cycle 20 multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of CDC20 mRNA CTD PMID:18720364 NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
JBrowse link
G Cdc42bpa CDC42 binding protein kinase alpha decreases expression ISO Azacitidine results in decreased expression of CDC42BPA mRNA CTD PMID:20823114 NCBI chr13:91,683,775...91,903,732
Ensembl chr13:91,684,007...91,903,732
JBrowse link
G Cdh1 cadherin 1 decreases methylation
increases expression
ISO Azacitidine results in decreased methylation of CDH1 promoter
Azacitidine results in increased expression of CDH1 mRNA
CTD PMID:17520682 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Cdh2 cadherin 2 increases expression EXP Azacitidine results in increased expression of CDH2 mRNA CTD PMID:18037191 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
increases expression
ISO [Azacitidine co-treated with Thalidomide] affects the expression of CDK1 mRNA
Azacitidine analog results in increased expression of CDK1 protein
CTD PMID:18324645 PMID:18720364 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO Azacitidine analog results in decreased expression of CDK2 protein CTD PMID:18324645 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO Azacitidine analog results in decreased expression of CDK4 protein CTD PMID:18324645 NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
ISO
EXP
Azacitidine analog results in increased expression of CDKN1A protein; Azacitidine results in increased expression of CDKN1A mRNA
[Azacitidine co-treated with entinostat] results in increased expression of CDKN1A mRNA; Azacitidine inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein]
[metacept-1 co-treated with Azacitidine] results in increased expression of CDKN1A
CTD PMID:18324645 PMID:19148494 PMID:20823114 PMID:21224363 PMID:25015661 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1c cyclin-dependent kinase inhibitor 1C increases expression ISO Azacitidine results in increased expression of CDKN1C mRNA CTD PMID:19194470 NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions
decreases methylation
affects methylation
increases expression
EXP
ISO
[Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene; [Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA
Azacitidine inhibits the reaction [Particulate Matter results in increased methylation of CDKN2A promoter]
Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene]
Azacitidine affects the methylation of CDKN2A gene
Azacitidine results in increased expression of CDKN2A mRNA
CTD PMID:17686055 PMID:18443271 PMID:21224363 PMID:22355787 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B decreases methylation
multiple interactions
affects response to substance
ISO Azacitidine results in decreased methylation of CDKN2B promoter
[metacept-1 co-treated with Azacitidine] results in increased expression of CDKN2B
CDKN2B promoter modified form affects the susceptibility to Azacitidine
CTD PMID:17611569 PMID:19148494 PMID:19194470 NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha decreases methylation
increases expression
ISO Azacitidine results in decreased methylation of CEBPA promoter
Azacitidine results in increased expression of CEBPA mRNA
CTD PMID:19194470 PMID:27590069 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Cenpa centromere protein A multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of CENPA mRNA CTD PMID:18720364 NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
JBrowse link
G Cenpf centromere protein F multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of CENPF mRNA CTD PMID:18720364 NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
JBrowse link
G Cenpo centromere protein O increases expression ISO Azacitidine results in increased expression of CENPO mRNA CTD PMID:19194470 NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314
JBrowse link
G Chat choline O-acetyltransferase increases expression ISO Azacitidine results in increased expression of CHAT mRNA; Azacitidine results in increased expression of CHAT protein CTD PMID:19151599 NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
JBrowse link
G Chga chromogranin A decreases expression ISO Azacitidine results in decreased expression of CHGA protein CTD PMID:20607034 NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
JBrowse link
G Chit1 chitinase 1 increases expression ISO Azacitidine results in increased expression of CHIT1 mRNA CTD PMID:20823114 NCBI chr13:45,565,841...45,613,593
Ensembl chr13:45,593,845...45,613,592
JBrowse link
G Chrm1 cholinergic receptor, muscarinic 1 affects expression ISO Azacitidine affects the expression of CHRM1 mRNA CTD PMID:19002953 NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
JBrowse link
G Chrm2 cholinergic receptor, muscarinic 2 affects expression ISO Azacitidine affects the expression of CHRM2 mRNA CTD PMID:19002953 NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
JBrowse link
G Chst14 carbohydrate sulfotransferase 14 increases expression EXP Azacitidine results in increased expression of CHST14 mRNA CTD PMID:27415467 NCBI chr 3:105,916,481...105,918,538
Ensembl chr 3:105,916,466...105,918,548
JBrowse link
G Ciita class II, major histocompatibility complex, transactivator multiple interactions
increases expression
ISO [Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]
Azacitidine results in increased expression of CIITA mRNA
CTD PMID:18829986 PMID:20823114 NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440
JBrowse link
G Cldn10 claudin 10 decreases expression ISO Azacitidine results in decreased expression of CLDN10 mRNA CTD PMID:19194470 NCBI chr15:95,862,785...95,954,526
Ensembl chr15:95,862,760...95,954,526
JBrowse link
G Cldn6 claudin 6 increases expression
decreases methylation
multiple interactions
ISO Azacitidine results in increased expression of CLDN6 mRNA
Azacitidine results in decreased methylation of CLDN6 promoter
[trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN6 promoter
CTD PMID:18661270 NCBI chr10:12,710,302...12,713,987 JBrowse link
G Cldn8 claudin 8 increases expression ISO Azacitidine results in increased expression of CLDN8 mRNA CTD PMID:18661270 NCBI chr11:27,875,857...27,878,106
Ensembl chr11:27,875,692...27,878,513
JBrowse link
G Cldn9 claudin 9 decreases methylation
multiple interactions
increases expression
ISO Azacitidine results in decreased methylation of CLDN9 promoter
[trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN9 promoter
Azacitidine results in increased expression of CLDN9 mRNA
CTD PMID:18661270 NCBI chr10:12,714,137...12,715,568 JBrowse link
G Cnnm2 cyclin and CBS domain divalent metal cation transport mediator 2 decreases expression ISO Azacitidine results in decreased expression of CNNM2 mRNA CTD PMID:19194470 NCBI chr 1:245,643,682...245,769,542
Ensembl chr 1:245,643,768...245,763,286
JBrowse link
G Col14a1 collagen type XIV alpha 1 chain increases expression ISO Azacitidine results in increased expression of COL14A1 mRNA CTD PMID:19194470 NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] CTD PMID:22841775 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col6a3 collagen type VI alpha 3 chain decreases expression ISO Azacitidine results in decreased expression of COL6A3 mRNA CTD PMID:20823114 NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
JBrowse link
G Col9a3 collagen type IX alpha 3 chain decreases expression ISO Azacitidine results in decreased expression of COL9A3 mRNA CTD PMID:18033690 NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465
JBrowse link
G Cox6a2 cytochrome c oxidase subunit 6A2 increases expression ISO Azacitidine results in increased expression of COX6A2 mRNA CTD PMID:20823114 NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
JBrowse link
G Cpe carboxypeptidase E increases expression ISO Azacitidine results in increased expression of CPE mRNA CTD PMID:20823114 NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
JBrowse link
G Cplx1 complexin 1 increases expression ISO Azacitidine results in increased expression of CPLX1 mRNA CTD PMID:20823114 NCBI chr14:1,184,638...1,216,392 JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter] CTD PMID:19155497 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
JBrowse link
G Creb3l4 cAMP responsive element binding protein 3-like 4 increases expression EXP Azacitidine results in increased expression of CREB3L4 mRNA CTD PMID:27415467 NCBI chr 2:175,690,340...175,696,084
Ensembl chr 2:175,690,335...175,695,932
JBrowse link
G Crem cAMP responsive element modulator decreases expression ISO Azacitidine results in decreased expression of CREM mRNA CTD PMID:20823114 NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
JBrowse link
G Cryaa crystallin, alpha A increases expression EXP Azacitidine results in increased expression of CRYAA protein CTD PMID:17105402 NCBI chr20:9,783,605...9,787,351
Ensembl chr20:9,783,605...9,787,349
JBrowse link
G Cryab crystallin, alpha B increases expression EXP Azacitidine results in increased expression of CRYAB protein CTD PMID:17105402 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
JBrowse link
G Csf1 colony stimulating factor 1 increases expression EXP Azacitidine results in increased expression of CSF1 mRNA CTD PMID:17156202 NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
JBrowse link
G Csn1s1 casein alpha s1 increases expression ISO Azacitidine results in increased expression of CSN1S1 mRNA CTD PMID:20823114 NCBI chr14:20,343,620...20,359,614
Ensembl chr14:20,343,619...20,359,614
JBrowse link
G Cst3 cystatin C increases expression ISO Azacitidine results in increased expression of CST3 mRNA CTD PMID:20823114 NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases methylation
increases expression
ISO Azacitidine results in decreased methylation of CXCL12 promoter
Azacitidine results in increased expression of CXCL12 mRNA; Azacitidine results in increased expression of CXCL12 protein
CTD PMID:19748759 NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases expression
ISO Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]]
Azacitidine results in increased expression of CYP1A1 mRNA
CTD PMID:11281733 PMID:12927368 PMID:17682057 PMID:27590069 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions
increases expression
ISO Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]
Azacitidine results in increased expression of CYP1A2 mRNA
CTD PMID:12927368 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions
increases expression
ISO Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]
Azacitidine results in increased expression of CYP1B1 mRNA
CTD PMID:12927368 PMID:27590069 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression ISO Azacitidine results in increased expression of CYP3A4 mRNA CTD PMID:27590069 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyth1 cytohesin 1 increases expression ISO Azacitidine results in increased expression of CYTH1 mRNA CTD PMID:19194470 NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,366,145...103,485,760
JBrowse link
G Dapk1 death associated protein kinase 1 affects methylation ISO Azacitidine affects the methylation of DAPK1 promoter CTD PMID:17557868 NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
JBrowse link
G Dcn decorin multiple interactions
decreases expression
ISO Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein]
Azacitidine results in decreased expression of DCN mRNA
CTD PMID:20823114 NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
JBrowse link
G Des desmin increases expression
multiple interactions
EXP
ISO
Azacitidine results in increased expression of DES mRNA; Azacitidine results in increased expression of DES protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA
CTD PMID:18037191 PMID:20823114 NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
JBrowse link
G Dhx9 DExH-box helicase 9 decreases expression ISO Azacitidine results in decreased expression of DHX9 mRNA CTD PMID:20823114 NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
JBrowse link
G Dio2 iodothyronine deiodinase 2 decreases expression ISO Azacitidine results in decreased expression of DIO2 mRNA CTD PMID:20823114 NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
JBrowse link
G Dlk1 delta like non-canonical Notch ligand 1 decreases methylation ISO Azacitidine results in decreased methylation of DLK1 promoter CTD PMID:19194470 NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
JBrowse link
G Dlx5 distal-less homeobox 5 increases expression ISO Azacitidine results in increased expression of DLX5 mRNA CTD PMID:17085970 NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407
JBrowse link
G Dlx6 distal-less homeobox 6 increases expression ISO Azacitidine results in increased expression of DLX6 mRNA CTD PMID:20823114 NCBI chr 4:34,984,264...34,989,926 JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions
decreases expression
ISO
EXP
[SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Arsenic Trioxide promotes the reaction [Azacitidine results in decreased expression of DNMT1 protein]
[Azacitidine co-treated with entinostat] results in decreased expression of DNMT1 protein; [Cisplatin co-treated with Azacitidine] results in decreased expression of DNMT1 protein
CTD PMID:19139132 PMID:19723570 PMID:21224363 PMID:28901456 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
JBrowse link
G Dpyd dihydropyrimidine dehydrogenase decreases methylation
multiple interactions
decreases response to substance
ISO Azacitidine results in decreased methylation of DPYD promoter
[Azacitidine results in decreased methylation of DPYD promoter] which results in increased expression of DPYD mRNA
DPYD protein results in decreased susceptibility to Azacitidine
CTD PMID:15501990 NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
JBrowse link
G Dusp1 dual specificity phosphatase 1 increases expression ISO Azacitidine results in increased expression of DUSP1 mRNA CTD PMID:20823114 NCBI chr10:16,680,489...16,683,276 JBrowse link
G Dusp6 dual specificity phosphatase 6 increases expression ISO Azacitidine results in increased expression of DUSP6 mRNA CTD PMID:21245298 NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] CTD PMID:19451745 NCBI chr 3:143,064,535...143,075,362 JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 decreases expression ISO Azacitidine results in decreased expression of EEF1A1 mRNA CTD PMID:20823114 NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
JBrowse link
G Efna3 ephrin A3 increases expression ISO Azacitidine results in increased expression of EFNA3 mRNA CTD PMID:20823114 NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
JBrowse link
G Egr2 early growth response 2 increases expression ISO Azacitidine results in increased expression of EGR2 mRNA CTD PMID:20823114 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
JBrowse link
G Eno2 enolase 2 decreases expression ISO Azacitidine results in decreased expression of ENO2 protein CTD PMID:20607034 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
JBrowse link
G Entpd1 ectonucleoside triphosphate diphosphohydrolase 1 increases expression ISO Azacitidine results in increased expression of ENTPD1 mRNA CTD PMID:20823114 NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
JBrowse link
G Esr1 estrogen receptor 1 increases expression ISO Azacitidine results in increased expression of ESR1 protein CTD PMID:22558281 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor multiple interactions ISO Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL4 promoter] CTD PMID:18945643 NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
JBrowse link
G Eya1 EYA transcriptional coactivator and phosphatase 1 decreases expression ISO Azacitidine results in decreased expression of EYA1 mRNA CTD PMID:20823114 NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO Azacitidine results in decreased expression of FADS2 mRNA CTD PMID:20823114 NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
JBrowse link
G Fam8a1 family with sequence similarity 8, member A1 increases expression ISO Azacitidine results in increased expression of FAM8A1 mRNA CTD PMID:19194470 NCBI chr17:18,026,601...18,035,509
Ensembl chr17:18,026,601...18,035,470
JBrowse link
G Faslg Fas ligand increases response to substance ISO Azacitidine results in increased susceptibility to FASLG protein CTD PMID:18829727 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fbln1 fibulin 1 increases expression ISO Azacitidine results in increased expression of FBLN1 mRNA CTD PMID:21245298 NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
JBrowse link
G Fen1 flap structure-specific endonuclease 1 multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of FEN1 mRNA CTD PMID:18720364 NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
JBrowse link
G Fgf7 fibroblast growth factor 7 decreases expression ISO Azacitidine results in decreased expression of FGF7 mRNA CTD PMID:20823114 NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
JBrowse link
G Filip1l filamin A interacting protein 1-like decreases expression ISO Azacitidine results in decreased expression of FILIP1L mRNA CTD PMID:20823114 NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA CTD PMID:20823114 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Foxp3 forkhead box P3 multiple interactions ISO [Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein; [Azacitidine results in decreased methylation of FOXP3 gene] which results in increased expression of FOXP3 protein CTD PMID:18493985 NCBI chr  X:14,908,494...14,924,994
Ensembl chr  X:14,908,494...14,923,838
JBrowse link
G Ftl1 ferritin light chain 1 decreases expression EXP Azacitidine results in decreased expression of FTL1 protein CTD PMID:17105402 NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725
JBrowse link
G Fyn FYN proto-oncogene, Src family tyrosine kinase increases expression ISO Azacitidine results in increased expression of FYN mRNA CTD PMID:21245298 NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
JBrowse link
G Gabrb1 gamma-aminobutyric acid type A receptor subunit beta1 increases expression ISO Azacitidine results in increased expression of GABRB1 mRNA CTD PMID:19194470 NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha decreases methylation
multiple interactions
increases expression
ISO Azacitidine results in decreased methylation of GADD45A promoter
[Azacitidine results in increased expression of GADD45A protein] which results in increased susceptibility to docetaxel
Azacitidine results in increased expression of GADD45A mRNA; Azacitidine results in increased expression of GADD45A protein
CTD PMID:19190346 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions ISO Azacitidine promotes the reaction [Depsipeptides results in increased expression of GADD45B] CTD PMID:18225533 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
JBrowse link
G Gata4 GATA binding protein 4 increases expression EXP Azacitidine results in increased expression of GATA4 mRNA; Azacitidine results in increased expression of GATA4 protein CTD PMID:18037191 NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
JBrowse link
G Gbp2 guanylate binding protein 2 decreases expression ISO Azacitidine results in decreased expression of GBP2 mRNA CTD PMID:20823114 NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 (I blood group) decreases expression ISO Azacitidine results in decreased expression of GCNT2 mRNA CTD PMID:20823114 NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
JBrowse link
G Gdf9 growth differentiation factor 9 increases expression ISO Azacitidine results in increased expression of GDF9 mRNA CTD PMID:23395740 NCBI chr10:37,589,200...37,599,970
Ensembl chr10:37,595,679...37,599,672
JBrowse link
G Gja1 gap junction protein, alpha 1 increases expression
decreases expression
EXP
ISO
Azacitidine results in increased expression of GJA1 protein
Azacitidine results in decreased expression of GJA1 mRNA
CTD PMID:18037191 PMID:20823114 NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
JBrowse link
G Gng7 G protein subunit gamma 7 affects methylation ISO Azacitidine affects the methylation of GNG7 promoter CTD PMID:18219292 NCBI chr 7:8,697,458...8,761,239
Ensembl chr 7:8,697,521...8,761,240
JBrowse link
G Gpkow G patch domain and KOW motifs increases expression ISO Azacitidine results in increased expression of GPKOW mRNA CTD PMID:20823114 NCBI chr  X:14,791,601...14,806,384
Ensembl chr  X:14,791,610...14,806,384
JBrowse link
G Gpnmb glycoprotein nmb decreases expression ISO Azacitidine results in decreased expression of GPNMB mRNA CTD PMID:20823114 NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
JBrowse link
G Grin2b glutamate ionotropic receptor NMDA type subunit 2B decreases methylation ISO Azacitidine results in decreased methylation of GRIN2B gene CTD PMID:18618247 NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
JBrowse link
G Guk1 guanylate kinase 1 increases expression ISO Azacitidine results in increased expression of GUK1 mRNA CTD PMID:20823114 NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107
JBrowse link
G Gzmb granzyme B multiple interactions ISO Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein] CTD PMID:19394699 NCBI chr15:30,343,361...30,346,792 JBrowse link
G H1f0 H1.0 linker histone increases expression ISO Azacitidine results in increased expression of H1-0 protein CTD PMID:16006241 NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions
ISO
EXP
Azacitidine results in increased expression of H2AX protein
Azacitidine inhibits the reaction [potassium bromate results in increased phosphorylation of H2AX protein]
CTD PMID:17991895 PMID:25015661 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G H3f4 H3.4 histone multiple interactions ISO Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter] CTD PMID:17698632 NCBI chr10:43,740,797...43,741,207 JBrowse link
G H4f16 H4 histone 16 multiple interactions ISO Azacitidine promotes the reaction [H4-16 protein modified form binds to CCNA1 promoter] CTD PMID:17698632
G Hgd homogentisate 1, 2-dioxygenase increases expression ISO Azacitidine results in increased expression of HGD mRNA CTD PMID:20823114 NCBI chr11:63,086,750...63,138,325
Ensembl chr11:63,086,752...63,138,323
JBrowse link
G Hgf hepatocyte growth factor increases expression ISO Azacitidine results in increased expression of HGF mRNA CTD PMID:19194470 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Hhex hematopoietically expressed homeobox increases expression ISO Azacitidine results in increased expression of HHEX mRNA CTD PMID:27590069 NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
JBrowse link
G Hmga1 high mobility group AT-hook 1 increases expression ISO Azacitidine results in increased expression of HMGA1 mRNA CTD PMID:20823114 NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
JBrowse link
G Hmga2 high mobility group AT-hook 2 increases expression
multiple interactions
ISO Azacitidine results in increased expression of HMGA2 mRNA
TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA]
CTD PMID:21245298 NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
JBrowse link
G Hmgb1 high mobility group box 1 decreases expression
multiple interactions
ISO Azacitidine results in decreased expression of HMGB1 mRNA
Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of HMGB1 mRNA]
CTD PMID:32278510 NCBI chr12:5,973,062...5,978,565 JBrowse link
G Hnf1a HNF1 homeobox A decreases methylation
multiple interactions
increases expression
ISO Azacitidine results in decreased methylation of HNF1A promoter
HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA]
Azacitidine results in increased expression of HNF1A mRNA; Azacitidine results in increased expression of HNF1A protein
CTD PMID:25953102 NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha increases expression ISO Azacitidine results in increased expression of HNF4A mRNA CTD PMID:27590069 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
JBrowse link
G Hoxa1 homeobox A1 multiple interactions
increases expression
ISO Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA]
Azacitidine results in increased expression of HOXA1 mRNA
CTD PMID:20823114 NCBI chr 4:81,255,814...81,258,504
Ensembl chr 4:81,255,883...81,258,504
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase decreases methylation
multiple interactions
increases expression
ISO Azacitidine results in decreased methylation of HPGD gene
trichostatin A promotes the reaction [Azacitidine results in increased expression of HPGD mRNA]
CTD PMID:19584167 NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 affects expression ISO Azacitidine affects the expression of HSD3B1 mRNA CTD PMID:18033690 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
JBrowse link
G Hsf1 heat shock transcription factor 1 decreases activity ISO Azacitidine results in decreased activity of HSF1 protein CTD PMID:34170685 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
JBrowse link
G Id1 inhibitor of DNA binding 1, HLH protein increases expression ISO Azacitidine results in increased expression of ID1 mRNA CTD PMID:19194470 NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
JBrowse link
G Id3 inhibitor of DNA binding 3, HLH protein increases expression ISO Azacitidine results in increased expression of ID3 mRNA CTD PMID:19194470 NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]; [Azacitidine results in increased expression of KIR2DL4 protein] which results in increased secretion of IFNG protein CTD PMID:18829986 PMID:18945643 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions
increases expression
ISO Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein]
Azacitidine results in increased expression of IGFBP1 mRNA
CTD PMID:20823114 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 increases expression ISO Azacitidine results in increased expression of IGFBP4 mRNA CTD PMID:20823114 NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
JBrowse link
G Il12b interleukin 12B increases expression ISO Azacitidine results in increased expression of IL12B mRNA CTD PMID:20823114 NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
EXP
ISO
Azacitidine results in increased expression of IL1B mRNA
Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]
CTD PMID:17156202 PMID:32894642 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions ISO Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein]; Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein] CTD PMID:19394699 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il4 interleukin 4 affects methylation ISO Azacitidine affects the methylation of IL4 promoter CTD PMID:18158872 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il6 interleukin 6 affects secretion
affects methylation
ISO Azacitidine affects the secretion of IL6 protein
Azacitidine affects the methylation of IL6 promoter
CTD PMID:18158872 PMID:18443271 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Il6r interleukin 6 receptor affects expression
multiple interactions
ISO [Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein; Azacitidine affects the expression of IL6R mRNA
[Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein
CTD PMID:18443271 NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
JBrowse link
G Isca1 iron-sulfur cluster assembly 1 increases expression ISO Azacitidine results in increased expression of ISCA1 mRNA CTD PMID:19194470 NCBI chr17:4,905,291...4,917,955
Ensembl chr17:4,905,287...4,917,955
JBrowse link
G Itgb1 integrin subunit beta 1 decreases expression ISO Azacitidine results in decreased expression of ITGB1 mRNA CTD PMID:20823114 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
JBrowse link
G Itgb2 integrin subunit beta 2 decreases expression ISO Azacitidine results in decreased expression of ITGB2 mRNA CTD PMID:19194470 NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
JBrowse link
G Itprid2 ITPR interacting domain containing 2 increases expression ISO Azacitidine results in increased expression of ITPRID2 mRNA CTD PMID:20823114 NCBI chr 3:64,536,707...64,573,978
Ensembl chr 3:64,536,707...64,573,978
JBrowse link
G Kdr kinase insert domain receptor increases expression EXP Azacitidine results in increased expression of KDR mRNA CTD PMID:18037191 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
JBrowse link
G Kif2c kinesin family member 2C multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of KIF2C mRNA CTD PMID:18720364 NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
JBrowse link
G Kir3dl1 killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 increases expression
decreases methylation
ISO Azacitidine results in increased expression of KIR3DL1 mRNA; Azacitidine results in increased expression of KIR3DL1 protein
Azacitidine results in decreased methylation of KIR3DL1 promoter
CTD PMID:18945643 PMID:19394699 NCBI chr 1:69,715,529...69,754,050
Ensembl chr 1:69,715,535...69,754,050
JBrowse link
G Klf6 Kruppel-like factor 6 increases expression
multiple interactions
ISO Azacitidine results in increased expression of KLF6 mRNA
TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA]
CTD PMID:21245298 NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
JBrowse link
G Krt19 keratin 19 increases expression ISO Azacitidine results in increased expression of KRT19 mRNA CTD PMID:20823114 NCBI chr10:85,075,835...85,080,552 JBrowse link
G Krt32 keratin 32 increases expression ISO Azacitidine results in increased expression of KRT32 mRNA CTD PMID:20823114 NCBI chr10:85,013,555...85,020,534
Ensembl chr10:85,013,554...85,020,534
JBrowse link
G Krt8 keratin 8 multiple interactions
increases expression
ISO Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA]
Azacitidine results in increased expression of KRT8 mRNA
CTD PMID:20823114 NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
JBrowse link
G Lama1 laminin subunit alpha 1 affects localization ISO Azacitidine affects the localization of LAMA1 protein CTD PMID:18033690 NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478
JBrowse link
G Lamb2 laminin subunit beta 2 increases expression ISO Azacitidine results in increased expression of LAMB2 mRNA CTD PMID:20823114 NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
JBrowse link
G Ldhb lactate dehydrogenase B increases expression ISO Azacitidine results in increased expression of LDHB mRNA CTD PMID:23437403 NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
JBrowse link
G Lims1 LIM zinc finger domain containing 1 increases expression ISO Azacitidine results in increased expression of LIMS1 mRNA CTD PMID:19194470 NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor decreases expression ISO Azacitidine results in decreased expression of LITAF mRNA CTD PMID:19194470 NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
JBrowse link
G LOC100911664 uncharacterized LOC100911664 increases expression ISO Azacitidine results in increased expression of C6ORF62 mRNA CTD PMID:19194470 NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020
JBrowse link
G LOC102553180 protocadherin alpha-1-like affects methylation ISO Azacitidine affects the methylation of PCDHA1 promoter CTD PMID:18204046
G LOC686035 similar to heat shock 70kDa protein 6 (HSP70B) increases expression ISO Azacitidine results in increased expression of HSPA6 mRNA CTD PMID:19194470 NCBI chr13:83,271,340...83,275,267 JBrowse link
G Ltb4r leukotriene B4 receptor decreases expression ISO Azacitidine results in decreased expression of LTB4R mRNA CTD PMID:20823114 NCBI chr15:29,263,126...29,265,716 JBrowse link
G Lyz2 lysozyme 2 increases expression ISO Azacitidine results in increased expression of LYZ mRNA CTD PMID:19194470 NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
JBrowse link
G Mad1l1 mitotic arrest deficient 1 like 1 decreases expression ISO Azacitidine results in decreased expression of MAD1L1 mRNA CTD PMID:19194470 NCBI chr12:14,320,892...14,630,750
Ensembl chr12:14,320,892...14,630,703
JBrowse link
G Map1a microtubule-associated protein 1A decreases expression ISO Azacitidine results in decreased expression of MAP1A mRNA CTD PMID:20823114 NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
JBrowse link
G Map2k5 mitogen activated protein kinase kinase 5 decreases expression ISO Azacitidine results in decreased expression of MAP2K5 mRNA CTD PMID:20823114 NCBI chr 8:63,625,220...63,852,090
Ensembl chr 8:63,625,221...63,851,983
JBrowse link
G Mapt microtubule-associated protein tau decreases expression ISO Azacitidine results in decreased expression of MAPT protein CTD PMID:16930453 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
JBrowse link
G Mcm5 minichromosome maintenance complex component 5 multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of MCM5 mRNA CTD PMID:18720364 NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
JBrowse link
G Mdc1 mediator of DNA damage checkpoint 1 increases expression ISO Azacitidine results in increased expression of MDC1 mRNA CTD PMID:20823114 NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO Azacitidine results in increased expression of MDM2 mRNA CTD PMID:20823114 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Mecp2 methyl CpG binding protein 2 multiple interactions ISO Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter] CTD PMID:17698632 NCBI chr  X:151,781,177...151,844,687
Ensembl chr  X:151,789,930...151,844,689
JBrowse link
G Mef2a myocyte enhancer factor 2a increases expression
affects expression
ISO Azacitidine results in increased expression of MEF2A
Azacitidine affects the expression of MEF2A protein
CTD PMID:12094073 PMID:19002953 NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
JBrowse link
G Mef2d myocyte enhancer factor 2D affects expression
increases expression
ISO Azacitidine affects the expression of MEF2D protein
Azacitidine results in increased expression of MEF2D
CTD PMID:12094073 PMID:19002953 NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457
JBrowse link
G Megf6 multiple EGF-like-domains 6 decreases expression ISO Azacitidine results in decreased expression of MEGF6 mRNA CTD PMID:19194470 NCBI chr 5:164,738,272...164,839,142
Ensembl chr 5:164,738,352...164,839,139
JBrowse link
G Mesd mesoderm development LRP chaperone decreases expression EXP Azacitidine results in decreased expression of MESD protein CTD PMID:17105402 NCBI chr 1:137,866,707...137,879,999
Ensembl chr 1:137,874,242...137,879,999
JBrowse link
G Mfap2 microfibril associated protein 2 decreases expression ISO Azacitidine results in decreased expression of MFAP2 mRNA CTD PMID:20823114 NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259
JBrowse link
G Mfge8 milk fat globule EGF and factor V/VIII domain containing affects expression ISO Azacitidine affects the expression of MFGE8 mRNA CTD PMID:18033690 NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase increases expression
decreases methylation
ISO Azacitidine results in increased expression of MGMT mRNA
Azacitidine results in decreased methylation of MGMT protein
CTD PMID:7511991 PMID:12807730 NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [Azacitidine co-treated with Thalidomide] affects the expression of MKI67 mRNA CTD PMID:18720364 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Mmp1 matrix metallopeptidase 1 increases expression ISO Azacitidine results in increased expression of MMP1 mRNA CTD PMID:20823114 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO metacept-1 inhibits the reaction [Azacitidine results in increased expression of MMP9] CTD PMID:19148494 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Morf4l2 mortality factor 4 like 2 decreases expression ISO Azacitidine results in decreased expression of MORF4L2 mRNA CTD PMID:20823114 NCBI chr  X:100,082,562...100,093,658
Ensembl chr  X:100,082,404...100,093,728
JBrowse link
G Mov10l1 Mov10 like RISC complex RNA helicase 1 increases expression ISO Azacitidine results in increased expression of MOV10L1 mRNA CTD PMID:20823114 NCBI chr 7:120,070,171...120,135,406
Ensembl chr 7:120,070,135...120,134,765
JBrowse link
G Msrb2 methionine sulfoxide reductase B2 increases expression ISO Azacitidine results in increased expression of MSRB2 mRNA CTD PMID:19194470 NCBI chr17:81,974,378...82,000,044
Ensembl chr17:81,974,196...82,000,043
JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase decreases expression ISO Azacitidine results in decreased expression of MTHFD2 mRNA CTD PMID:20823114 NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
JBrowse link
G Mtrex Mtr4 exosome RNA helicase increases expression ISO Azacitidine results in increased expression of MTREX mRNA CTD PMID:20823114 NCBI chr 2:44,500,326...44,560,624
Ensembl chr 2:44,461,444...44,560,627
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression
multiple interactions
ISO Azacitidine analog results in decreased expression of MYC mRNA
MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]
CTD PMID:18045574 PMID:19451745 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Myf5 myogenic factor 5 increases expression ISO Azacitidine results in increased expression of MYF5 mRNA CTD PMID:18938140 NCBI chr 7:42,802,946...42,806,177
Ensembl chr 7:42,802,946...42,806,177
JBrowse link
G Myh7 myosin heavy chain 7 increases expression EXP Azacitidine results in increased expression of MYH7 mRNA; Azacitidine results in increased expression of MYH7 protein CTD PMID:17105402 NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
JBrowse link
G Myl2 myosin light chain 2 increases expression EXP Azacitidine results in increased expression of MYL2 mRNA CTD PMID:17105402 NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983
JBrowse link
G Myod1 myogenic differentiation 1 increases expression EXP
ISO
Azacitidine results in increased expression of MYOD1 mRNA CTD PMID:18037191 PMID:18938140 NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
JBrowse link
G Myog myogenin increases expression ISO Azacitidine results in increased expression of MYOG mRNA CTD PMID:18938140 NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
JBrowse link
G Ncam1 neural cell adhesion molecule 1 increases expression EXP Azacitidine results in increased expression of NCAM1 mRNA CTD PMID:18037191 NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
JBrowse link
G Nefl neurofilament light chain increases expression ISO Azacitidine results in increased expression of NEFL mRNA CTD PMID:20823114 NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 increases expression ISO Azacitidine results in increased expression of NFATC1 mRNA CTD PMID:20823114 NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
JBrowse link
G Niban1 niban apoptosis regulator 1 increases expression
multiple interactions
ISO Azacitidine results in increased expression of NIBAN1 mRNA
TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA]
CTD PMID:21245298 NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
JBrowse link
G Nkx2-5 NK2 homeobox 5 increases expression ISO Azacitidine results in increased expression of NKX2-5 mRNA CTD PMID:18557828 NCBI chr10:16,340,428...16,347,004
Ensembl chr10:16,344,159...16,346,934
JBrowse link
G Nlgn3 neuroligin 3 increases expression ISO Azacitidine results in increased expression of NLGN3 mRNA CTD PMID:20823114 NCBI chr  X:66,427,926...66,457,378
Ensembl chr  X:66,429,458...66,451,876
JBrowse link
G Nme2 NME/NM23 nucleoside diphosphate kinase 2 increases expression EXP Azacitidine results in increased expression of NME2 protein CTD PMID:17105402 NCBI chr10:78,898,097...78,903,600
Ensembl chr10:78,897,770...78,903,538
JBrowse link
G Nmi N-myc (and STAT) interactor increases expression ISO Azacitidine results in increased expression of NMI mRNA CTD PMID:21245298 NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
JBrowse link
G Nom1 nucleolar protein with MIF4G domain 1 decreases expression ISO Azacitidine results in decreased expression of NOM1 mRNA CTD PMID:20823114 NCBI chr 4:5,891,220...5,910,741
Ensembl chr 4:5,892,909...5,909,709
JBrowse link
G Nphp1 nephrocystin 1 increases expression ISO Azacitidine results in increased expression of NPHP1 mRNA CTD PMID:20823114 NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234